Last reviewed · How we verify
RAAS inhibition therapy
At a glance
| Generic name | RAAS inhibition therapy |
|---|---|
| Also known as | Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin II receptor blockers (ARBs) |
| Sponsor | Palatin Technologies, Inc |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease (PHASE2)
- The Plasma Metabolomics Profiling of Primary Aldosteronism
- Telmisartan Versus Enalapril in Heart Failure With Reduced Ejection Fraction Patients With Moderately Impaired Kidney Functions (NA)
- Lokelma for RAAS Maximisation in CKD & Heart Failure. (PHASE3)
- Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure (PHASE2)
- Registry for Ambulant Therapy With RAS-Inhibitors in Hypertension-patients in Germany
- Study of Inflammation and Oxidative Stress in Persons Undergoing Dialysis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RAAS inhibition therapy CI brief — competitive landscape report
- RAAS inhibition therapy updates RSS · CI watch RSS
- Palatin Technologies, Inc portfolio CI